Chronic kidney disease drug trial success in Oxfordshire
Oxfordshire residents who participated in a clinical trial for a drug to treat chronic kidney disease are “thrilled” it has been approved for…
Source: oxfordmail.co.uk
William Herrington News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from William Herrington. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In William Herrington Today - Breaking & Trending Today
Benefits, Mechanisms of SGLT2 Inhibitors in Diabetic Kidney Disease, Other Communities
Although SGLT2 inhibitors are not a cure of diabetic kidney disease, this treatment can help reduce the risk and manage the disease either alone or with complementary therapies.
Source: pharmacytimes.com
Jardiance recommended for the treatment of adults with chronic kidney disease in the EU
The Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has granted a positive opinion recommending Jardiance empagliflozin for the treatment of adults with chronic kidney disease CKD Boehringer Ingelheim and Eli Lilly and Company NYSE LLY announced today.1
Source: businesswireindia.com
Boehringer Ingelheim: Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice1,2 Phase III trial also demonstrated
Source: finanznachrichten.de
Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
/PRNewswire/ -- EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults...
Source: prnewswire.com